Noam Yarom1,2, Allan Hovan3, Paolo Bossi4, Anura Ariyawardana5,6, Siri Beier Jensen7, Margherita Gobbo8, Hanan Saca-Hazboun9, Abhishek Kandwal10, Alessandra Majorana11, Giulia Ottaviani8, Monica Pentenero12, Narmin Mohammed Nasr13, Tanya Rouleau14, Anna Skripnik Lucas15, Nathaniel Simon Treister16,17, Eyal Zur18, Vinisha Ranna19, Anusha Vaddi20, Karis Kin Fong Cheng21, Andrei Barasch22, Rajesh V Lalla23, Sharon Elad20. 1. Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel. Noam.yarom@sheba.health.gov.il. 2. School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel. Noam.yarom@sheba.health.gov.il. 3. British Columbia Cancer - Vancouver Centre, Vancouver, Canada. 4. Medical Oncology, ASST-Spedali Civili, University of Brescia, Brescia, Italy. 5. College of Medicine and Dentistry, James Cook University, Cairns, Queensland, Australia. 6. Metro South Oral Health, Queensland Health, Brisbane, Australia. 7. Department of Dentistry and Oral Health, Faculty of Health, Aarhus University, Aarhus, Denmark. 8. Division of Oral Medicine and Pathology, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. 9. Al-Maha Cancer foundation, Bethlehem, Palestine. 10. Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himayalan University, Dehradun, Uttarakhand, India. 11. Department of Medical and Surgical Specialties, Radiological Science and Public Health, Dental School University of Brescia, Brescia, Italy. 12. Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Turin, Turin, Italy. 13. Special Needs Dentistry, Dental Services, Directorate General of Health Services-Muscat Governorate, Ministry of Health, Muscat, Oman. 14. Dental Oncology Program, Health Sciences North, North East Cancer Center, Sudbury, ON, Canada. 15. Medical Oncology Service, Department of Medicine, NYU Langone Perlmutter Cancer Center, New York, NY, USA. 16. Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA. 17. Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA. 18. Compounding Solutions, Tel-Mond, Israel. 19. Department of Oral and Maxillofacial Surgery, The Mount Sinai Hospital, New York, NY, 10029, USA. 20. Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA. 21. Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 22. Division of Oncology, Weill Cornell Medical College, New York, NY, USA. 23. Section of Oral Medicine, University of Connecticut School of Dental Medicine, Farmington, CT, USA.
Abstract
PURPOSE: To update the clinical practice guidelines for the use of natural and miscellaneous agents for the prevention and/or treatment of oral mucositis (OM). METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible. RESULTS: A total of 78 papers were identified within the scope of this section, out of which 29 were included in this part, and were analyzed with 27 previously reviewed studies. A new Suggestion was made for oral glutamine for the prevention of OM in head and neck (H&N) cancer patients receiving radiotherapy with concomitant chemotherapy. The previous Recommendation against the use of parenteral glutamine for the prevention of OM in hematopoietic stem cell transplantation (HSCT) patients was re-established. A previous Suggestion for zinc to prevent OM in H&N cancer patients treated with radiotherapy or chemo-radiotherapy was reversed to No Guideline Possible. No guideline was possible for other interventions. CONCLUSIONS: Of the vitamins, minerals, and nutritional supplements studied for the management of OM, the evidence supports a Recommendation against parenteral glutamine in HSCT patients and a Suggestion in favor of oral glutamine in H&N cancer patients for the management of OM.
PURPOSE: To update the clinical practice guidelines for the use of natural and miscellaneous agents for the prevention and/or treatment of oral mucositis (OM). METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible. RESULTS: A total of 78 papers were identified within the scope of this section, out of which 29 were included in this part, and were analyzed with 27 previously reviewed studies. A new Suggestion was made for oral glutamine for the prevention of OM in head and neck (H&N) cancerpatients receiving radiotherapy with concomitant chemotherapy. The previous Recommendation against the use of parenteral glutamine for the prevention of OM in hematopoietic stem cell transplantation (HSCT) patients was re-established. A previous Suggestion for zinc to prevent OM in H&N cancerpatients treated with radiotherapy or chemo-radiotherapy was reversed to No Guideline Possible. No guideline was possible for other interventions. CONCLUSIONS: Of the vitamins, minerals, and nutritional supplements studied for the management of OM, the evidence supports a Recommendation against parenteral glutamine in HSCT patients and a Suggestion in favor of oral glutamine in H&N cancerpatients for the management of OM.
Authors: N M A Blijlevens; J P Donnelly; A H J Naber; A V M B Schattenberg; B E DePauw Journal: Support Care Cancer Date: 2005-03-15 Impact factor: 3.603
Authors: M F Raphael; A M den Boer; W J W Kollen; H Mekelenkamp; F C H Abbink; G J L Kaspers; K Zomer-Kooijker; B H W Molmans; W J E Tissing Journal: Support Care Cancer Date: 2013-11-07 Impact factor: 3.603
Authors: P M Anderson; N K Ramsay; X O Shu; N Rydholm; J Rogosheske; R Nicklow; D J Weisdorf; K M Skubitz Journal: Bone Marrow Transplant Date: 1998-08 Impact factor: 5.483
Authors: Noam Yarom; Anura Ariyawardana; Allan Hovan; Andrei Barasch; Virginia Jarvis; Siri Beier Jensen; Yehuda Zadik; Sharon Elad; Joanne Bowen; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-06-14 Impact factor: 3.603
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Wanessa Miranda-Silva; Wagner Gomes-Silva; Yehuda Zadik; Noam Yarom; Abdul Rahman Al-Azri; Catherine H L Hong; Anura Ariyawardana; Deborah P Saunders; M Elvira Correa; Praveen R Arany; Joanne Bowen; Karis Kin Fong Cheng; Wim J E Tissing; Paolo Bossi; Sharon Elad Journal: Support Care Cancer Date: 2020-11-06 Impact factor: 3.603
Authors: Aida Kusiak; Barbara AlicjaJereczek-Fossa; Dominika Cichońska; Daniela Alterio Journal: Int J Environ Res Public Health Date: 2020-04-03 Impact factor: 3.390